• Why Jemperli and Zejula will be key assets in GSK's India oncology portfolio?

    Источник: Buzz FX / 26 авг 2025 05:45:49   America/Los_Angeles


    British pharmaceutical giant GlaxoSmithKline (GSK) has entered India’s oncology space with the launch of two advanced therapies, Jemperli (dostarlimab) and Zejula (niraparib), in a move that goes beyond simple portfolio expansion.
    Read more...
Опубликовать